Xp11.2 translocation renal cell carcinoma with TFE3 gene fusion: A case report

  • Authors:
    • Xiang Pan
    • Jing Quan
    • Liwen Zhao
    • Wenhua Li
    • Benlin Wei
    • Shangqi Yang
    • Yongqing Lai
  • View Affiliations

  • Published online on: November 13, 2017     https://doi.org/10.3892/mco.2017.1497
  • Pages:83-85
Metrics: PDF 0 views | HTML 0 views
0

Abstract

Xp11.2 translocation renal cell carcinoma (RCC) with transcription factor E3 (TFE3) gene fusion is a rare tumor, and the prognosis of this tumor is poorer compared with that of other subtypes of RCC. The patient presented herein was a 70‑year‑old man who presented with a solid mass sized ~8.2x6.1 cm in the right kidney and underwent radical right nephrectomy. Following pathological and immunohistochemical (IHC) examination and fluorescent in situ hybridization (FISH), the patient was diagnosed with Xp11.2 translocation RCC with TFE3 gene fusion. These tumors are more commonly encountered in children rather than in adults, and adult Xp11.2 translocation RCC is associated with a poorer prognosis compared with its pediatric counterpart. IHC assay and FISH are important diagnostic methods. However, there is currently no established effective treatment for Xp11.2 RCC.

Related Articles

Journal Cover

January 2018
Volume 8 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Pan, X., Quan, J., Zhao, L., Li, W., Wei, B., Yang, S., & Lai, Y. (2018). Xp11.2 translocation renal cell carcinoma with TFE3 gene fusion: A case report. Molecular and Clinical Oncology, 8, 83-85. https://doi.org/10.3892/mco.2017.1497
MLA
Pan, X., Quan, J., Zhao, L., Li, W., Wei, B., Yang, S., Lai, Y."Xp11.2 translocation renal cell carcinoma with TFE3 gene fusion: A case report". Molecular and Clinical Oncology 8.1 (2018): 83-85.
Chicago
Pan, X., Quan, J., Zhao, L., Li, W., Wei, B., Yang, S., Lai, Y."Xp11.2 translocation renal cell carcinoma with TFE3 gene fusion: A case report". Molecular and Clinical Oncology 8, no. 1 (2018): 83-85. https://doi.org/10.3892/mco.2017.1497